TrialHaematologica2021

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Mahesh Swaminathan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.